авторефераты диссертаций БЕСПЛАТНАЯ БИБЛИОТЕКА РОССИИ

КОНФЕРЕНЦИИ, КНИГИ, ПОСОБИЯ, НАУЧНЫЕ ИЗДАНИЯ

<< ГЛАВНАЯ
АГРОИНЖЕНЕРИЯ
АСТРОНОМИЯ
БЕЗОПАСНОСТЬ
БИОЛОГИЯ
ЗЕМЛЯ
ИНФОРМАТИКА
ИСКУССТВОВЕДЕНИЕ
ИСТОРИЯ
КУЛЬТУРОЛОГИЯ
МАШИНОСТРОЕНИЕ
МЕДИЦИНА
МЕТАЛЛУРГИЯ
МЕХАНИКА
ПЕДАГОГИКА
ПОЛИТИКА
ПРИБОРОСТРОЕНИЕ
ПРОДОВОЛЬСТВИЕ
ПСИХОЛОГИЯ
РАДИОТЕХНИКА
СЕЛЬСКОЕ ХОЗЯЙСТВО
СОЦИОЛОГИЯ
СТРОИТЕЛЬСТВО
ТЕХНИЧЕСКИЕ НАУКИ
ТРАНСПОРТ
ФАРМАЦЕВТИКА
ФИЗИКА
ФИЗИОЛОГИЯ
ФИЛОЛОГИЯ
ФИЛОСОФИЯ
ХИМИЯ
ЭКОНОМИКА
ЭЛЕКТРОТЕХНИКА
ЭНЕРГЕТИКА
ЮРИСПРУДЕНЦИЯ
ЯЗЫКОЗНАНИЕ
РАЗНОЕ
КОНТАКТЫ


Pages:     | 1 | 2 ||

«Федеральное Государственное Бюджетное Учреждение Гематологический Научный Центр Минздрава России На правах ...»

-- [ Страница 3 ] --

61. Chang M., Nakagawa P.A., Williams S.A., et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;

102:887– 62. Cohen Y.C., Djulbegovic B., Shamai-Lubovits O. et al. The bleeding risc and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch. Int. Med. 2000;

160:1630-1638.

63. Culic S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br.J.Haematol. 2003;

120:909-910.

64. Deckmyn H., De Reys S. Functional effects of human antiplatelet antibodies.

Semin.Thromb.Hemost. 1995;

21:46-59.

65. Donald M Arnold, Ishac Nazi & John G Kelton New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. J.Drugs. 2009;

18(6) 1- 66. Donato H., Pic A., Martinez M., et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: A multicentered study from Argentina. Pediatr Blood Cancer. 2008;

52(4):491-496.

67. Drachman J.G. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood. 2004;

103:390-398.

68. Emilia G., Longo G., Luppi M., et al. Helikobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood. 2001;

97:812 14.

- 112 69. Emmons R.V., Reid D.M., Cohen R.L., et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased destruction. Blood. 1996;

87:4068-71.

70. Fabris F., Tassan T., Ramon R., et al. Age as the major predictive factor of longterm response to splenectomy in immune thrombocytopenic purpura.

Br.J.Haematol. 200;

112:637-40.

71. Figueroa M., Gehlsen J., Hammond D., et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N.Engl. J.Med. 1993;

328: 1226-1229.

72. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;

94:909–13.

73. Gaines A.R. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rho(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2000;

95:2523-29.

74. George J.N., Rascob G.E. Idiopathic thrombocytopenic purpura: diagnosis and management. University of Oklahoma Health Center. 1998;

76(5):211-214.

75. George J.N., Wooif S.H., Rascob G.E., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;

88:3-40.

76. Gernsheimer Т. Chronic Idiopathic Thrombocytopenic Purpura: Mechanisms of Pathogenesis. Oncologist. 2009;

14(10): 12-21.

77. Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high– dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomized multicenter trial. Lancet.

2002;

359:23–29.

- 113 78. Godeau B., Porcher R., Fain O. et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;

112(4):999-1004.

79. Godeau B., Provan D., Bussel J. Immune thrombocytopenic purpura in adults.

Curt Opin Hematol. 2007;

14(5):535-536.

80. Griffiths J, Sia W, Shapiro A.M., Tataryn I., Turner A.R. Laparoscopic splenectomy for the treatment of refractory immune thrombocytopenia in pregnancy. J Obstet Gynaecol Can. 2005;

27(8): 771-774.

81. Gu J., Lu L., Xu R., Chen X. Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. Chin Med J (Engl) 2002;

115:983–6.

82. Hamidpour M., Behrendt M., Griffiths B. Et al. The isolation and characterization of antiplatelet antibodies. Eur J. Haematol. 2006;

76(4):331-8.

83. Harrington W.J., Minnish V., Hollingsworth J.W. et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J.

Lab. Clin. Med. 1951;

38:1-10.

84. Harrington W.J., Sprague C.C., Mihnnich V. et al. Imunologic mechanism in idiopathic and neonatal thrombocytopenic purpura. Ann.Intern.Med. 1953;

v.38,N.3, p.433-469.

85. Hegde U.M. Platelet antibodies in immune thrombocytopenia. Blood Rev. 1992.-V.6.-№1.-р.34-42.

86. Kappers-Klunne M.C., Veer M.B. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br.J.Haematol. 2001;

-р.114:121-125.

87. Karly P. Garnock-Jones and Susan J. Keam. Eltrombopag. J. Drugs. 2009;

р.69(5): 567–576.

- 114 88. Kojouri K., Veseli S.K., Terrell D.R., et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count response, and surgical complications. Blood 2004;

-р.104:2623-34.

89. Kohda K., Kuga T., Kogawa K., et al. Effect of Helikobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br.J.

Haematol. 2002;

-р.118:584-88.

90. Kuwana M, Okazaki Y, Kaburaki J, et al. Spleen is the primary site for activation of plateletreactive T and B cells in patients with immune thrombocytopenic purpura. J. Immunol. 2003;

-р.168:3675–82.

91. Kuwana K, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb–IIIa in immune thrombocytopenic purpura. Role in production of antiplatelet autoantibody. J.

Clin. Invest. 1998;

-р.102:1393– 92. Kuwana M., Okazaki Y., Kaburaki J. et al. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J.Immunol. 2002;

-р.168:3675-3682.

93. Lasarus A.H., Crow A.R. Mechanism of action of IVIG and anti-D in ITP.

Transfus. Apher. Sci. 2003;

-р.28:249-255.

94. Lechner K., Weltermann A., Pabinger I., Autoimmunthrombocytopenie (AITP) des Erwachsenen: Klinik, Diagnose und Therapie. Wien Klin Wochenschr.

2006;

118/9-10.

95. Lefkovits J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N. Engl. J. Med. 1995;

-р.1553-1559.

96. Levin G.G., Kozinets G.I., Novoderzhkina J.K. Blood cells research using method of microinterferometry. Proceeding SPIE.- V/2982.- 1997;

-p.490-495.

- 115 97. Lorton J.E. Management of asplenic patients. Br. J. Haematol. 1993;

р.84:566-69.

98. Louwes H., Zeinali Lathori O., Vellenga E. et al. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am. J. Med. 1999;

-р.106:430-434.

99. Marcaccio M.J. Laparoscopic splenectomy in chronic idiopathic thrombocytopenic purpura. Semin. Hematol. 2000;

-р.37:267-74.

100. McMillan R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes. J.Pediatr Hematol Oncol. 2003;

-р.25:

57-61.

101. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin. Hematol. 2000;

-р.37: 239-248.

102. McMillan R., Wang L., Tomer A., et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult chronic ITP patients. Blood. 2004;

-р.103:1364–69.

103. Meyr D., Girma J.P., von Willebrand faktor: structure and function. Thromb.

Haemost. 1993;

V. 70 №1. -р.99-104.

104. Meseguer J., Esteban M.A., Rodrigues A. Are trombocytes and platelets true phagocytes? Microscopy Research and Technique. 2002;

-p.491-497.

105. Michel M., Cooper N., Frissora J., et al. Does Helikobacter pylori initiate or perpetuate immune thrombocytopenic purpura? Blood. 2003;

-р.103:890-96.

106. Najean Y., Rain J., Billotey C. The site of destruction of autologous Inlabelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 568 patients with 268 splenectomies.

Br.J. Haematol. 1997;

-р.97:547-50.

- 116 107. Neylon A.J., Saunders P.W., Howard M.R., et al. Clinically significant newly presented autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br. J. Haematol. 2003;

-р.122:966-974.

108. Newman G.C., Novoa M.V., Fodero E.M. et al. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br. J. Haematol 2001;

-р.112:1076-8.

109. Portielje J.E., Westendorp R.G., Kluin–Nelemans H.C., Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;

-р.97:

2549–2554.

110. Provan D., Stasi R., Hewlond A. et al. Interstional consensus report on the investigation and management of primary Immune Thrombocytopenia. Blood. 2010;

р.115, 168-186.

111. Recommendations of the advisory committee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. Morbid. Mortal. Wkly. Rep. 1993;

-р.42:1-11.

112. Reiner A., Gernsheimer T., Slichter S. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;

-р.85:351-358.

113. Scaradavou A., Woo B., Wolosci B.M. et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997;

р.89:2689-700.

114. Stahl D, Hoemberg M, Cassens U, Pachmann U, Sibrowski W. Evidence that human autoimmune thrombocytopenia mediated by both immunoglobulin isotypes IgM and IgG is an independent disease entity. Eur. J. Haematol. 2005;

75(4): 318-27.

115. Stasi R., Stipa E., Masi Sciarra A., et al. Long–term observation of adults with chronic idiopathic thrombocytopenic purpura. American Journal of Medicine. 1995;

-р.98:436–442.

- 117 116. Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;

98(4):952-7.

117. Vainchenker W, Debili N, Methia N, Mouthon MA, Wendling F.

Hematopoiesis and its regulation: comparison between erythropoiesis and megakaryocytopenias. Bull Acad Natl Med. 1994;

-р.178:753–78.

118. Veneri D, Franchini M, Raffaelli R, Musola M, Memmo A, Franchi M, Pizzolo G. Idiopathic thrombocytopenic purpura in pregnancy: Analysis of consecutive cases followed at a single Italian institution. Ann Hematol. 2006;

85(8):552-4.

119. Von dem Borne A, Folman C, van den Oudenrijn S, Linthorst G, de Jong S, de Haas M. The potential role of thrombopoietin in idiopathic thrombocytopenic purpura. Blood Rev. 2002;

16:57–9.

120. Wang T., Wang Z., Yang R. Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura. Crit Rev Oncol. Hematol. 2011;

77(3):172–83.

121. Webert K.E., Mittal R., Sigouin C., Heddle N.M., Kelton J.G., A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood. 2003;

102(13).

122. Win N., Rowley M., Pollard C., Beard J., Hambley H., Booker M. Severe gestational thrombocytopenia: to treat or not to treat. Hematology. 2005;

10(1): 69-72.

123. White J.G. Giant electron-dense chains, clusters and granules in megakayocytes and platelets with normal dense bodies: an an inherited thrombocytopenic disorder. Platelets. 2003;

-р.109-121.

124. Won Y.W., Moon W., Yon Y.S., Oh H.S., Choi J.H., Lee Y.Y., Kim I.S., Choi I.Y., Ahn M.J. Clinical aspects of pregnancy and delivery in patients with chronic idiopathic thrombocytopenic purpura (ITP). Korean J. Intern. Med. 2005;

20(2).

- 118 125. Wrobel G., Dobaczewski G., Patcowski D. et al. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Ped. Blood Cancer. 2006;

47: 729-730.



Pages:     | 1 | 2 ||
 





 
© 2013 www.libed.ru - «Бесплатная библиотека научно-практических конференций»

Материалы этого сайта размещены для ознакомления, все права принадлежат их авторам.
Если Вы не согласны с тем, что Ваш материал размещён на этом сайте, пожалуйста, напишите нам, мы в течении 1-2 рабочих дней удалим его.